3 phospho-JNK (Thr183/Tyr185), JNK, phospho-ERK1/2 (Thr202/Tyr204), ERK1/2, phospho-p38 MAPK (Thr180/Tyr182), p38 MAPK, insulin receptor substrate (IRS)-1, phospho-IRS-1(Ser612), phospho-tyrosine, and glucose transporter 4 (GLUT4) were from Cell Signaling Technology (Danvers, MA); Antibodies to PI3K p85 and nephrin were from Abcam (Cambridge, MA). To document the loading controls, the membrane was reprobed with a primary antibody against housekeeping protein β-actin (ProteinTech Group). For measurement of tyrosine phosphorylation of IRS-1, cellular lysates were analyzed by immunoprecipitation with an antibody to IRS-1, and detected by Western blot analysis using an antibody to phospho-tyrosine. To determine the binding of p85 to IRS-1, immunoprecipitation was also performed using an antibody to IRS-1 and detected by Western blot analysis using an antibody to PI3K p85.
Immunofluorescence：Immunofluorescent staining was performed using a modified protocol as previously described (4) . Cells were washed in ice-cold PBS and put on ice to arrest glucose transport after insulin stimulation. GLUT4 staining was analyzed using a Nikon ECLIPSE E 800 fluorescence microscope (Nikon, Tokyo, Japan). Images of nephrin fluorescein isothiocyanate (FITC) and F-actin tetramethyl-rhodamine isothiocyanate (TRITC) were obtained by confocal laser-scanning microscopy using a LSM780 laser scanning confocal microscope (ZEISS, Germany) equipped with a Plan-Apochromat 63×/1.4 objective. Images were assembled in the Adobe Photoshop 7.0 software package.
RNA interference:
Small interference RNA to NOD2 (siRNA-NOD2) was synthesized and constructed into pRNAT-U6.1/Neo to get shRNA-NOD2 by Biomics Biotechnologies Co., Ltd.
(Nantong, Jiangsu, China). The DNA target sequence for shRNA-NOD2 (5'-GCTCTGTATT Table S1 . Clinical data and relative mRNA levels of NOD2 in diabetic subjects with and without DN, nondiabetic normal subjects, and other nephrotic subjects.
SCr, serum creatinine; UPE, urinary protein excretion; eGFR, estimated GFR; HbA1c, hemoglobin A1c; F, female; M, male; DPN, diabetic peripheral neuropathy; DR, diabetic retinopathy; IHD, ischemic heart disease; CVA, cerebrovascular accident; N, not present; NA, not applicable/not available. 
